PE20090605A1 - Composiciones de fenilalanina amoniaco-liasa procariotica y metodos del tratamiento del cancer usando composiciones de la misma - Google Patents

Composiciones de fenilalanina amoniaco-liasa procariotica y metodos del tratamiento del cancer usando composiciones de la misma

Info

Publication number
PE20090605A1
PE20090605A1 PE2008001395A PE2008001395A PE20090605A1 PE 20090605 A1 PE20090605 A1 PE 20090605A1 PE 2008001395 A PE2008001395 A PE 2008001395A PE 2008001395 A PE2008001395 A PE 2008001395A PE 20090605 A1 PE20090605 A1 PE 20090605A1
Authority
PE
Peru
Prior art keywords
compositions
procariotica
phenylalanine
cancer
treatment
Prior art date
Application number
PE2008001395A
Other languages
English (en)
Inventor
Michael C Vellard
Paul A Fitzpatrick
Emil D Kakkis
Daniel J Wendt
Mubarack Muthalif
Sean M Bell
Augustus O Okhamafe
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40363135&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090605(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of PE20090605A1 publication Critical patent/PE20090605A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UNA VARIANTE DE FENILALANINA AMINOLIASA (PAL) PROCARIOTICA TAL COMO ANABAENA VARIABILIS PAL (avPAL) DONDE EN LAS POSICIONES 64, 318, 503 Y 565 SE HAN SUSTITUIDO CON RESIDUO DE SERINA; ADEMAS COMPRENDE POLIETILENGLICOL, DONDE LA PROPORACION avPAL:PEG ES DE 1:3; B) UN PORTADOR SELECCIONADO DE L-FENILALANINA, ACIDO TRANS-CINAMICO, ACIDO BENZOICO, ENTRE OTROS. DICHA COMPOSICION MEJORA LA ACTIVIDAD CATALITICA Y/O ESTABILIDAD DE PAL PROCARIOTICA EN EL TRATAMIENTO DEL CANCER
PE2008001395A 2007-08-17 2008-08-15 Composiciones de fenilalanina amoniaco-liasa procariotica y metodos del tratamiento del cancer usando composiciones de la misma PE20090605A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6612507P 2007-08-17 2007-08-17

Publications (1)

Publication Number Publication Date
PE20090605A1 true PE20090605A1 (es) 2009-05-16

Family

ID=40363135

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001395A PE20090605A1 (es) 2007-08-17 2008-08-15 Composiciones de fenilalanina amoniaco-liasa procariotica y metodos del tratamiento del cancer usando composiciones de la misma

Country Status (23)

Country Link
US (4) US7537923B2 (es)
EP (1) EP2175875B1 (es)
JP (1) JP5584120B2 (es)
CN (1) CN101803492B (es)
AR (2) AR067972A1 (es)
AU (1) AU2008289549B2 (es)
BR (2) BR122018072594B8 (es)
CA (1) CA2687028C (es)
CL (1) CL2008002390A1 (es)
CY (1) CY1118222T1 (es)
DK (1) DK2175875T3 (es)
ES (1) ES2602618T3 (es)
HR (1) HRP20161474T1 (es)
HU (1) HUE029510T4 (es)
LT (1) LT2175875T (es)
MX (1) MX2009012261A (es)
PE (1) PE20090605A1 (es)
PL (1) PL2175875T3 (es)
PT (1) PT2175875T (es)
RU (2) RU2009141987A (es)
SI (1) SI2175875T1 (es)
TW (1) TWI418787B (es)
WO (1) WO2009025760A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7537923B2 (en) * 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
EP3381445B1 (en) * 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
WO2010014225A2 (en) 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
WO2011078667A2 (en) 2009-12-22 2011-06-30 Dsm Ip Assets B.V. Method of finding a biocatalyst having ammonia lyase activity
PT3025728T (pt) * 2010-02-04 2018-11-05 Biomarin Pharm Inc Método para purificar variantes procarióticas de fenilalanina amónia-liase
WO2012075173A2 (en) 2010-12-01 2012-06-07 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
AU2013295621A1 (en) * 2012-07-27 2015-03-12 University Of North Texas Genetically modified probiotic for the treatment of phenylketonuria (PKU) disease
DK2986722T3 (da) * 2013-04-18 2019-05-13 Codexis Inc Manipulerede phenylalaninammoniak-lyasepolypeptider
CA2930665A1 (en) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
CN106456744A (zh) 2014-04-01 2017-02-22 鲁比厄斯治疗法股份有限公司 用于免疫调节的方法和组合物
EP3928787A1 (en) 2014-04-16 2021-12-29 Codexis, Inc. Engineered tyrosine ammonia lyase
EP4005590A1 (en) 2014-04-29 2022-06-01 Bio-Cancer Treatment International Ltd. Methods and compositions for modulating the immune system with arginase i
WO2016008886A1 (en) * 2014-07-14 2016-01-21 Danmarks Tekniske Universitet Processes for the production of hydroxycinnamic acids using polypeptides having tyrosine ammonia lyase activity
KR20220123342A (ko) 2014-12-22 2022-09-06 코덱시스, 인코포레이티드 인간 알파-갈락토시다제 변이체
SG11201811603WA (en) 2016-07-26 2019-02-27 Biomarin Pharm Inc Novel adeno-associated virus capsid proteins
IT201600086488A1 (it) * 2016-08-22 2018-02-22 St Microelectronics Srl Dispositivo a semiconduttore e corrispondente procedimento
CN110573175A (zh) 2017-02-13 2019-12-13 科德克希思公司 工程化苯丙氨酸氨裂合酶多肽
US11739345B2 (en) 2018-05-09 2023-08-29 Biomarin Pharmaceutical Inc. Methods of treating phenylketonuria
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
CA3102968A1 (en) 2018-06-12 2019-12-19 Codexis, Inc. Engineered tyrosine ammonia lyase
WO2020123286A1 (en) 2018-12-14 2020-06-18 Codexis, Inc. Engineered tyrosine ammonia lyase
CA3123598A1 (en) 2018-12-20 2020-06-25 Codexis, Inc. Human alpha-galactosidase variants
US11987823B2 (en) 2019-08-30 2024-05-21 Societe Des Produits Nestle S.A. Engineered lipase variants
IL294082A (en) 2019-12-20 2022-08-01 Codexis Inc Transgenic variants of acid alpha-glycosidase
AR122409A1 (es) 2020-04-03 2022-09-07 Biomarin Pharm Inc Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas
US11959108B2 (en) 2020-08-28 2024-04-16 Codexis, Inc. Engineered protease variants
BR112023003643A2 (pt) 2020-08-28 2023-03-28 Codexis Inc Amilase recombinante, composição, sequência de polinucleotídeo recombinante, vetor de expressão, célula hospedeira, métodos para produzir uma amilase recombinante e para tratar e/ou prevenir os sintomas de insuficiência pancreática, composição farmacêutica para o tratamento de insuficiência pancreática, e, uso
WO2022245924A1 (en) 2021-05-19 2022-11-24 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252822A (en) 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4562151A (en) 1983-09-06 1985-12-31 Monsanto Company Stabilization of L-phenylalanine ammonia-lyase enzyme
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5212939A (en) * 1991-12-04 1993-05-25 Pratt Jr John M Marine mooring swivel fitting
JP2930723B2 (ja) 1992-11-19 1999-08-03 アンティキャンサー インコーポレーテド 抗メチオニン化学療法における抗腫瘍薬としてのメチオニナーゼの使用
ATE361984T1 (de) 1992-12-04 2007-06-15 Me Medical Enzymes Ag Gentechnologisch hergestellte glutaminase und ihre verwendung in therapie
DK75593D0 (es) 1993-06-25 1993-06-25 Novo Nordisk As
GB9418092D0 (en) * 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
KR0164757B1 (ko) * 1995-06-13 1999-01-15 김광호 공조장치의 살균집진장치와 그 방법
DE69638117D1 (de) 1995-09-21 2010-03-04 Genentech Inc Varianten des menschlichen Wachstumshormons
CU22585A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.
US6548644B1 (en) 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US5981239A (en) 1997-09-24 1999-11-09 Great Lakes Chemical Corp. Synthesis of optically active phenylalanine analogs using Rhodotorula graminis
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6686164B1 (en) 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
JP4812167B2 (ja) 1999-02-12 2011-11-09 モレキュラー インサイト ファーマスーティカルズ インコーポレイテッド 薬物輸送用マトリックス、ならびにその作成方法および使用方法
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
WO2001079469A2 (en) 2000-04-14 2001-10-25 University Of South Carolina Research Foundation Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses
US6967097B2 (en) 2000-07-24 2005-11-22 Pcbu Services, Inc. Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
US6939941B2 (en) * 2001-09-12 2005-09-06 Toray Fine Chemicals Co., Ltd. Preparation of polysulfide compositions
IL162811A0 (en) 2002-02-26 2005-11-20 Du Pont Method for the recombination of genetic elements
US20080124275A1 (en) 2002-11-14 2008-05-29 The Scripps Research Institute Crystalline Form of Fatty Acid Amide Hydrolase (Faah)
JP2008513027A (ja) 2004-09-17 2008-05-01 バイオマリン ファーマシューティカル インコーポレイテッド フェニルアラニンアンモニアーリアーゼの改変体および化学的に修飾された改変体
CA2614769A1 (en) * 2005-03-10 2006-09-21 Verenium Corporation Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
DE102006032167B4 (de) 2006-07-12 2014-11-27 Evonik Degussa Gmbh Verfahren zur Herstellung von Triallylisocyanurat (TAIC)
US20090011400A1 (en) 2006-12-01 2009-01-08 The Salk Institute for Biological Studies and The Regents of the University of California Substrate switched ammonia lyases and mutases
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
WO2010014225A2 (en) 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase

Also Published As

Publication number Publication date
MX2009012261A (es) 2010-03-15
RU2553343C2 (ru) 2015-06-10
US7560263B2 (en) 2009-07-14
HRP20161474T1 (hr) 2016-12-30
AR117389A2 (es) 2021-08-04
BRPI0811589A2 (pt) 2014-10-29
AR067972A1 (es) 2009-10-28
JP2010536759A (ja) 2010-12-02
RU2009141987A (ru) 2011-05-20
WO2009025760A2 (en) 2009-02-26
HUE029510T4 (en) 2017-05-29
EP2175875B1 (en) 2016-10-05
ES2602618T3 (es) 2017-02-21
SI2175875T1 (sl) 2017-01-31
AU2008289549B2 (en) 2014-02-06
CN101803492B (zh) 2014-05-07
EP2175875A2 (en) 2010-04-21
CN101803492A (zh) 2010-08-11
TW200911283A (en) 2009-03-16
CY1118222T1 (el) 2017-06-28
BRPI0811589B1 (pt) 2020-05-12
JP5584120B2 (ja) 2014-09-03
US20090263369A1 (en) 2009-10-22
PT2175875T (pt) 2016-11-21
CA2687028C (en) 2016-02-16
WO2009025760A3 (en) 2009-06-25
CL2008002390A1 (es) 2009-05-29
US20090047265A1 (en) 2009-02-19
US7790433B2 (en) 2010-09-07
DK2175875T3 (en) 2016-11-21
HUE029510T2 (hu) 2017-02-28
BR122018072594B8 (pt) 2021-07-27
US7537923B2 (en) 2009-05-26
LT2175875T (lt) 2016-12-12
AU2008289549A1 (en) 2009-02-26
US20100278802A1 (en) 2010-11-04
US20090047268A1 (en) 2009-02-19
BRPI0811589B8 (pt) 2021-05-25
PL2175875T3 (pl) 2017-04-28
CA2687028A1 (en) 2009-02-26
BR122018072594B1 (pt) 2020-10-27
TWI418787B (zh) 2013-12-11
RU2012134838A (ru) 2014-03-20

Similar Documents

Publication Publication Date Title
PE20090605A1 (es) Composiciones de fenilalanina amoniaco-liasa procariotica y metodos del tratamiento del cancer usando composiciones de la misma
CL2011000653A1 (es) Compuestos derivados del acido 1-amino-2-ciclobutil-etil-boronico; composicion farmaceutica; polvo liofilizado y metodo para obtenerlo; y uso en el tratamiento del cancer.
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
PE20090315A1 (es) Composiciones de fenilalanina amoniaco liasa procariotica y metodos para usar composiciones de la misma
ECSP055671A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa
WO2010084115A3 (en) Antiviral agents
CL2008000690A1 (es) Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
PE20130198A1 (es) Composiciones solidas
PA8576201A1 (es) Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
AR047928A1 (es) Derivados de tetrahidropiridoindol
EA200700976A1 (ru) Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой
CY1107342T1 (el) Χρηση παραγωγων νιτριλιου ως φαρμακο
CL2007002689A1 (es) Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
MX2013008478A (es) 1, 4 riazepinas/sulfonas como inhibidores de beta secretasa 1 (base1) y/o beta secretasa 2 (bace2).
RU2016135039A (ru) Композиция для обработки поверхностных дефектов
BR112013028679A2 (pt) inibidores do vírus da hepatite c
TW200626527A (en) Novel hexafluoroisopropanol derivatives
MX2012005689A (es) Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos.
MX2012007225A (es) Composicion farmaceutica que comprende mezcla de solventes y derivado o analogo de vitamina d.
PH12015501122A1 (en) Flowable peroxide containing oral care compositions
AR057648A1 (es) Composicion de metaflumizona para la administracion topica
BRPI0408299A (pt) inibidores de catepsina s
BRPI0621347B8 (pt) composição farmacêutica para aumentar a produção de eritrócitos e para o tratamento de anemia
CO7170181A2 (es) Nueva composición de alfentanilo para el tratamiento del dolor agudo
EA200700023A1 (ru) Разрыхляющаяся при пероральном приёме фармацевтическая композиция, содержащая рисперидон

Legal Events

Date Code Title Description
FG Grant, registration